Yazar "Cetingul, N" seçeneğine göre listele
Listeleniyor 1 - 20 / 49
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Alpha-interferon-2b treatment for chronic hepatitis-B infection in children with cancer(Oxford Univ Press United Kingdom, 1996) Cetingul, N; Kavakli, K; Vergin, C; Oztop, S; Nili, G; Aydodu, S; Ozacar, T; Bilgic, A; Yuce, G; Yaci, RWe have evaluated the efficacy of treatment with recombinant Interferon-2b (IFN-2b) in 12 children with cancer who developed chronic hepatitis-B infection, Seven of them had lymphoblastic leukaemia and others had solid tumours, Seven cases were male. Mean age was 10.5 years with a range of 5-16 years. Chronic Hepatitis B was diagnosed biochemically, serologically and histopathologically. They were HBsAg(+), NBV-DNA(+), and HCV(-), HIV(-). Seven cases were HBeAg(+) and two of them were anti-Delta IgG(+), Liver biopsy revealed chronic active hepatitis in six cases and persistent hepatitis in three eases. IFN rues given at the dose of 5 MU/m(2) three times a week, subcutaneously for 6 months. It was well tolerated, After IFN therapy, ALT levels returned to normal in seven cases, All cases were still BBsAg(+). Four of them seroconverted to anti-HBe antibody. Loss of serum HBV-DNA in three cases, but 11 cases showed a marked decrease after IFN, The control liver biopsies showed that histopathological activity index was diminished in five cases. Other 16 patients, serving as control, received no therapy. Five of them were leukaemia and others were solid tumours. Twelve cases were male, Mean age was 9.3 years with a range of 4-19 years. After 6 months, only one patient lost HBV-DNA and three of them seroconverted to anti-HBe with normalization of ALT values. In our study, IFN treatment favourably influenced the prepress of chronic hepatitis B in children with cancer.Öğe Assessment of chemotherapy-induced changes in bone sarcomas: Clinical experience with Tc-99(m)-MDP three-phase dynamic bone scintigraphy(Lippincott Williams & Wilkins, 1999) Ozcan, Z; Burak, Z; Kumanlioglu, K; Sabah, D; Basdemir, G; Bilkay, B; Cetingul, N; Ozkilic, HThe aim of this study was to evaluate the value of three-phase dynamic bone scintigraphy (TPBS) in the assessment of the response of bone sarcomas to pre-operative chemotherapy and to correlate serial scintigraphic changes with histological findings. The study group comprised 27 patients (osteogenic sarcoma, n = 20; Ewing's sarcoma, n = 5; malignant fibrous histiocytoma, (n = 2) with a mean age of 19.2 years. All patients received (99T)c(m)-methylene diphosphonate TPBS before and after pre-operative chem otherapy. Each phase of the imaging procedure was interpreted qualitatively and quantitatively. The percentage of tumour necrosis was analysed on resection materials following surgery. Histologically, 12 patients were non-responsive (tumour necrosis less than 90%) and 15 patients were responsive (tumour necrosis more than 90%). A decrease in the tumour blood flow ratio and extension were the most notable findings in the responders. The moan change in the tumour blood flow ratio following therapy was 58.7 +/- 8.3% and 19.9 +/- 26.6% (P < 0.005) in responders and non-responders respectively. The accuracy of three-phase imaging and static bone scintigraphy was 88% and 74% respectively Since bone scintigraphy is a valuable technique owing to its ability to detect distant metastases in clinically early disease, TPBS should be helpful in monitoring therapy effects without any additional cost or radiation dose. ((C) 1999 Lippincott Williams & Wilkins).Öğe Assessment of neutrophil chemotaxis and random migration in children with thalassemia major(Hemisphere Publ Corp, 1996) Kutukculer, N; Kutlu, O; Nisli, G; Oztop, S; Cetingul, N; Caglayan, SNeutrophil chemotaxis and random migration were evaluated in 21 patients with thalassemia major and 21 healthy controls by a filter technique (Boyden chamber). Chemotactic and random migrations in patient group were found to be defective, which may partially account for the increased susceptibility to infection occasionally observed in these patients. The effects of serum ferritin bevels, transferrin saturations that show iron overload, total count of blood transfusions for chronic immunostimulation, desferrioxamine therapy, and splenectomy on these neutrophil functions were examined in thalassemic patients in order to determine whether they are responsible for these defective functions because the mechanism of abnormal neutrophil chemotaxis and random mobility in thalassemic patients is not still clear.Öğe Beta-thalassemia alleles in Aegean region of Turkey: Effect on clinical severity of disease(Hemisphere Publ Corp, 1997) Nisli, G; Kavakli, K; Aydinok, Y; Oztop, S; Cetingul, NBeta (beta) globin gene analysis teas performed in 54 homozygous beta-thalassemia patients followed up in the Pediatric Hematology Department of Medical School of Ege University. The spectrum of beta-thalassemia alleles and their effect on clinical severity of disease were investigated. Twelve different mutations were determined in our patients. The six most frequent alleles, IVSI-110 (G-A), IVSI-6 (T-C), IVSI-I (G-A), IVSII-745 (C-G), Cd39 (C-T), and FSC8, account for 80.6% of all the disease genes. Eleven percent of the chromosomes could not be identified with the probes used in this study. In 38 patients both of whose beta-thalassemia alleles were identified, the beta-thalassemia alleles were found to be the major determinant of the clinical severity of disease. The clinical progress of disease was also closely related to the deg? ee of iron overload.Öğe Combined administration of hepatitis B vaccine and hepatitis B immune globulin in children with cancer(Hemisphere Publ Corp, 1996) Kavakli, K; Cetingul, N; Oztop, S; Nisli, G; Ozacar, TÖğe Concurrent expressions of CD34 and CD133 antigens on stem cells derived from umbilical cord and peripheral blood(Nature Publishing Group, 2005) Kansoy, S; Bayram, N; Kantar, M; Aksoylar, S; Keskinoglu, A; Donmez, A; Cetingul, NÖğe Dysosteosclerosis: Clinicoradiologic findings including brain MRI(Pergamon-Elsevier Science Ltd, 1997) Sener, RN; Yalman, O; Cetingul, N; Tutuncuoglu, S; Kavakli, K; Ustun, EEDysosteosclerosis is a very rare bone dysplasia associated with sclerosis and platyspondyly, This paper reports the clinicoradiologic and MR imaging findings in this rare condition, The primary brain MR imaging finding was retarded white matter matter myelination, (C) 1998 Elsevier Science Limited. All rights reserved.Öğe Early determination of nutritional problems in pediatric cancer patients(Turkish J Pediatrics, 1997) Kurugol, Z; Egemen, A; Cetingul, N; Kavakli, K; Nisli, G; Oztop, SMild and marginal malnutrition must be identified to prevent the development of severe protein-energy malnutrition in pediatric cancer patients. We aimed to evaluate nutritional status and determine daily energy, protein and micronutrient intake to identify mild or marginal malnutrition in pediatric cancer patients. Daily energy, protein and micronutrient intake, anthropometric measurements and biochemical indices were studied in 45 patients (25 in remission, 20 newly diagnosed or relapsed) who consumed energy, protein, vitamins and minerals below the recommended quantities. According to the weight-for-height index, 23 children (51.1%) were determined to he malnourished. Absolute and relative prealbumin values were 19.4 +/- 7.2 mg/dl and 74.3 +/- 29.1 mg/dl in the remission group, and 14.8 +/- 5.1 mg/dl and 58.1 +/- 23.3 in the active disease group, respectively (p<0.05). Relative prealbumin values were found to be low in 63.6 percent of nonmalnourished children, and 80 percent of children with mild malnutrition. We conclude that malnutrition is common in pediatric cancer patients, and prealbumin is a reliable and sensitive indicator of mild and marginal malnutrition. Determining prealbumin values and assessing the deficiency of micro-and macronutrients before malnutrition Is detected by anthropometric measures may provide a warning that nutritional problems may occur.Öğe Endocrine complications in patients with beta-thalassemia major(Oxford Univ Press, 2002) Aydinok, Y; Darcan, S; Polat, A; Kavakli, K; Nisli, G; Coker, M; Kantar, M; Cetingul, NThirty-seven patients with thalassemia major (TM) were studied to determine the extent and rate of endocrine complications. Mean haemoglobin and ferritin concentrations were 8.8 +/- 0.6 and 3597 +/- 1931, respectively. Provocation tests for growth hormone secretion were applied in patients with standing heights below the third centile and/or growth velocities below the 10th centile. Sexual maturation was assessed by using the criteria of Tanner. Glucose metabolism was assessed by fasting plasma glucose and glucose tolerance test. Basal thyroid function was measured and thyrotropin-releasing hormone tolerance test was carried out. Growth retardation was found in 40 per cent of patients and growth hormone deficiency was a prominent cause of growth retardation. Gonadal dysfunction was detected in 47 per cent of patients. Hypothyroidism was observed in 16 per cent and impaired glucose metabolism in 10.8 per cent patients. The high rate of endocrine disturbances indicates the importance of regular follow-up of thalassemia major patients with regard to endocrine complications of the disease.Öğe Experience of the Izmir pediatric oncology group on neuroblastoma: IPOG-NBL-92 protocol(Taylor & Francis Inc, 2003) Olgun, N; Kansoy, SS; Aksoylar, S; Cetingul, N; Vergin, C; Oniz, H; Sarialioglu, F; Kantar, M; Uysal, K; Tuncyurek, M; Kargi, A; Aktas, S; Bayol, U; Karaca, I; Arikan, A; Balik, E; Aktug, TJ; Elmas, N; Kovanlikaya, A; Kinay, M; Anacak, Y; Degirmenci, B; Burak, ZThis multicentric study aimed to bring neuroblastoma patients together under IPOG-NBL-92 protocol and evaluate the results within the period between 1992 and 2001 in Izmir. Sixty-seven neuroblastoma patients from 4 pediatric oncology centers in Izmir were included in the study. IPOG-NBL-92 protocol modified from German Pediatric Oncology (GPO)-NB-90 protocol was applied: Patients in stage 1 received only surgery, while surgery plus 4 chemotherapy courses (cisplatin, vincristine, ifosfamide) were given in stage 2 and surgery plus 6 chemotherapy courses (cisplatin, vincristine, ifosfamide, epirubicin, cyclophosphamide) were given in stages 3 and 4 patients. In patients who were kept in complete remission (CR), a maintenance therapy of one year was applied. Radiotherapy was given to the primary site following induction chemotherapy plus surgery in stages 3 and 4 patients with partial remission (PR). The stages of the patients were as follows: 5% in stage 1, 39% in stage 3, 49% in stage 4, and 7% in stage 4S. Primary tumor site was abdomen in 88% of cases. CR rates were as 100% in stage 1, 76% in stage 3, 35% in stage 4, and 75% in stage 4S. Relapse was observed in 32% of patients in a median of 19 months. The median follow-up time for survivors was 33 (17-102) months. Five-year OS rate was 31% and the EFS rate was 30% in all patients. Five-year overall and event-free survival rates were 63 and 30% in stage 3, but 6 and 5%, respectively, in stage 4 patients. Univariate analysis established that the age, stage, primary tumor site, and high LDH and NSE levels conferred a significant difference. The IPOG-NBL-92 protocol has proved to be satisfactory with tolerable toxicity and reasonable CR and survival rates. However, more effective treatments suitable to Turkey's social and economic conditions are urgently needed for children over 1 year of age with advanced neuroblastoma.Öğe Experience of the Izmir pediatric oncology group on neuroblastoma: IPOG-NBL-92 protocol(Taylor & Francis Inc, 2003) Olgun, N; Kansoy, SS; Aksoylar, S; Cetingul, N; Vergin, C; Oniz, H; Sarialioglu, F; Kantar, M; Uysal, K; Tuncyurek, M; Kargi, A; Aktas, S; Bayol, U; Karaca, I; Arikan, A; Balik, E; Aktug, TJ; Elmas, N; Kovanlikaya, A; Kinay, M; Anacak, Y; Degirmenci, B; Burak, ZThis multicentric study aimed to bring neuroblastoma patients together under IPOG-NBL-92 protocol and evaluate the results within the period between 1992 and 2001 in Izmir. Sixty-seven neuroblastoma patients from 4 pediatric oncology centers in Izmir were included in the study. IPOG-NBL-92 protocol modified from German Pediatric Oncology (GPO)-NB-90 protocol was applied: Patients in stage 1 received only surgery, while surgery plus 4 chemotherapy courses (cisplatin, vincristine, ifosfamide) were given in stage 2 and surgery plus 6 chemotherapy courses (cisplatin, vincristine, ifosfamide, epirubicin, cyclophosphamide) were given in stages 3 and 4 patients. In patients who were kept in complete remission (CR), a maintenance therapy of one year was applied. Radiotherapy was given to the primary site following induction chemotherapy plus surgery in stages 3 and 4 patients with partial remission (PR). The stages of the patients were as follows: 5% in stage 1, 39% in stage 3, 49% in stage 4, and 7% in stage 4S. Primary tumor site was abdomen in 88% of cases. CR rates were as 100% in stage 1, 76% in stage 3, 35% in stage 4, and 75% in stage 4S. Relapse was observed in 32% of patients in a median of 19 months. The median follow-up time for survivors was 33 (17-102) months. Five-year OS rate was 31% and the EFS rate was 30% in all patients. Five-year overall and event-free survival rates were 63 and 30% in stage 3, but 6 and 5%, respectively, in stage 4 patients. Univariate analysis established that the age, stage, primary tumor site, and high LDH and NSE levels conferred a significant difference. The IPOG-NBL-92 protocol has proved to be satisfactory with tolerable toxicity and reasonable CR and survival rates. However, more effective treatments suitable to Turkey's social and economic conditions are urgently needed for children over 1 year of age with advanced neuroblastoma.Öğe Fibrin glue for circumcision in severe hemophilia(F K Schattauer Verlag Gmbh, 1997) Kavakli, K; Nisli, G; Polat, A; Aydinok, Y; Oztop, S; Cetingul, N; Ozcan, C; Avanoglu, A; Ulman, I; Gokdemir, AÖğe Hepatitis B vaccination in children with thalassemia, hemophilia and cancer(Williams & Wilkins, 1996) Kavakli, K; Nisli, G; Cetingul, N; Oztop, S; Bilgic, A; Ozacar, TÖğe Histiocytic syndromes in children(Turkish J Pediatrics, 1997) Cetingul, N; Oztop, S; Kavakli, K; Ozunan, I; Nisli, G; Hekimgil, MThe ''histiocytes'' are a group of proliferative disorders of the mononuclear phagocyte system whose etiologies are basically unknown. The majority of childhood histiocytoses are expressions of excessive numbers of Langerhans cells, representing so-called Langerhans cell histiocytosis. Fifteen patients who were diagnosed with histiocytosis syndrome at the Pediatric Hematology and Oncology Department of Ege University Hospital between October 1986 and January 1995 were included in this study. The majority of the patients had Langerhans cell histiocytosis (LCH), and skeletal involvement was the most common manifestation. A good response to radiotherapy and chemotherapy was obtained by our patients with unifocal and multifocal involvement of LCH. Two patients with disseminated LCH died with progressive disease. In the patient with Rosai-Dorfman disease, a partial response was obtained with prednisone. The patient with malignant histiocytosis died during a relapse at the end of one year. Organ dysfunction and the patient's age are important factors affecting the outcome of the disease.Öğe Human Parvovirus B 19 seroprevalance in Turkish hemophiliac children(Blackwell Science Ltd, 1998) Kavakli, K; Ozacar, T; Polat, A; Zeytinoglu, A; Aydinok, Y; Kantar, M; Nisli, G; Bilgic, A; Cetingul, NÖğe Immune deficiencies following cancer treatment in children(Oxford Univ Press, 2003) Kantar, M; Cetingul, N; Kansoy, S; Kutukculer, N; Aksu, GThe aim of this study was to determine serum immunoglobulins, IgG subclasses, lymphocyte subsets, and serum protective antitoxin levels of tetanus and diphtheria, and to investigate specific antibody response to tetanus and diphtheria vaccines in children with cancer who have been treated for leukemias and solid tumors. Forty patients with different types of childhood malignancies were enrolled in this study and their lymphocyte subsets, serum Ig A, M, G and IgG subclass concentrations were determined at completion of chemotherapy and 6 months later. We measured serum diphtheria (D) and tetanus (T) antitoxin levels and investigated specific antibody responses against DT vaccines at 6 months. Only the leukemic children had low CD19+ cells at completion of chemotherapy and 6 months later. The patients with solid tumors had reduced CD4+ cells, but increased natural killer cells at completion of chemotherapy. Serum IgA and IgM levels were decreased in leukemic patients after chemotherapy. There were no IgG subclass deficiency. Forty-two per cent of the patients did not have protective serum T antitoxins. All patients produced high levels of DT antibodies by vaccination. Immune system changes recover by 6 months after cancer therapy in children. Children with solid tumors, as well as leukemias, should be followed-up in terms of immune deficiencies. A repeat dose of tetanus toxoid should be recommended at 6 months.Öğe Immune deficiencies following cancer treatment in children(Oxford Univ Press, 2003) Kantar, M; Cetingul, N; Kansoy, S; Kutukculer, N; Aksu, GThe aim of this study was to determine serum immunoglobulins, IgG subclasses, lymphocyte subsets, and serum protective antitoxin levels of tetanus and diphtheria, and to investigate specific antibody response to tetanus and diphtheria vaccines in children with cancer who have been treated for leukemias and solid tumors. Forty patients with different types of childhood malignancies were enrolled in this study and their lymphocyte subsets, serum Ig A, M, G and IgG subclass concentrations were determined at completion of chemotherapy and 6 months later. We measured serum diphtheria (D) and tetanus (T) antitoxin levels and investigated specific antibody responses against DT vaccines at 6 months. Only the leukemic children had low CD19+ cells at completion of chemotherapy and 6 months later. The patients with solid tumors had reduced CD4+ cells, but increased natural killer cells at completion of chemotherapy. Serum IgA and IgM levels were decreased in leukemic patients after chemotherapy. There were no IgG subclass deficiency. Forty-two per cent of the patients did not have protective serum T antitoxins. All patients produced high levels of DT antibodies by vaccination. Immune system changes recover by 6 months after cancer therapy in children. Children with solid tumors, as well as leukemias, should be followed-up in terms of immune deficiencies. A repeat dose of tetanus toxoid should be recommended at 6 months.Öğe Lipid Secreting Breast-Carcinoma In Childhood - a Case-Report(Hippokrates Verlag Gmbh, 1993) Balik, E; Taneli, C; Cetinkursun, S; Yazici, M; Cetingul, N; Erhan, Y; Haydaroglu, A; Oztop, SA ten-year-old girl was admitted to our hospital with a mass in the left breast after a local recurrence following a resection done in a district hospital three months earlier. A modified radical mastectomy with axillary lymph node dissection was performed in our department. Histological examination revealed a lipid secreting carcinoma (lipid-rich carcinoma) of the breast. To our knowledge she is the first case in childhood in the literature and is therefore reported.Öğe Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children(Taylor & Francis Inc, 2004) Aksoylar, S; Cetingul, N; Kantar, M; Karapinar, D; Kavakli, K; Kansoy, SThe aim of this study was to evaluate the efficacy and safety of meropenum plus amikacin compared with piperacillin-tazobactam plus netilmicin for initial empirical antibiotic treatment of high-fisk febrile neutropenia in children with cancer. Patients with hematologic malignancy (leukemia or stage III/IV non-Hodgkin lymphoma) who presented with fever and neutrepenia (ANC < 500/mm(3)) and patients with solid tumors who presented with fever and severe. neutropenia (ANC < 100/mm(3)) were considered to be at high risk and eligible,for this study. In this prospective study, 33 patients with 50 febrile neutropenic episodes received iv meropenem (20 mg/kg every 8 h) plus amikacin (15 mg/kg/d in 2 divided doses) (in 31 episodes) or piperacillin/tazobactam (100 mg/4 mg/kg every 8 h) plus netilmicin (7 mg/kg every 24 h) (in 19 episodes). Clinical response was determined at 72 h and at completion of the therapy. The groups were comparable in terms of age, sex, initial ANC, use of growth factors, and classification of the infections. An infection was documented microbiologically in 12 episodes (39%) in the meropenem plus amikacin group and in 8 episodes (42%) in the piperacillin/tazobactam plus netilmicin group. Of the 22 microbiological isolates, 37% were gram-positives, 45 % were gram-negatives, and 18 % were fungi. Most of the clinically documented infections were of lower respiratory tract, gastrointestinal mucosa, or urinary tract origin. The mean duration of neutropenia was 9 days in both groups. Fever persisted for 1-30 days (mean 3 vs. 5 days). The success rate with initial empiric therapy was 52 % in the meropenem plus amikacin and 42 % in the piperacillin/tazobactam plus netmicin g-roup, respectively (p =.5). Total success rate (with or without modification) was 97 % vs. 90 % in the episodes. Three patients died due to infection (I vs. 2 patients). No major adverse effects were, observed in each group. Empirical therapy with meropenem plus amikacin or piperacillin/azobactam plus netilmicin effective and safe in pediatric cancer patients.Öğe Neuropsychologic sequelae in the long-term survivors of childhood acute lymphoblastic leukemia(Hemisphere Publ Corp, 1999) Cetingul, N; Aydmok, Y; Kantar, M; Oniz, H; Kavakli, K; Yalman, O; Erermis, S; Celebisoy, N; Akyurekli, O; Oztop, S; Nisli, GThe neurotoxicity of either systemic chemotherapy or central nervous system prophylaxis was studied in 19 children treated for acute lymphoblastic leukemia (ALL). They had completed ALL therapy at least a year before and survived more than 5 pears after diagnosis. The duration between age at diagnosis and age at investigation was 8.6 +/- 2.7 years (5-15 years). Neuropsychologic tests, cranial magnetic resonance imaging (MRI), and evoked potentials (EP) were studied. Seventeen healthy siblings were taken as a control group. Emotional evaluation was done using the childhood depression inventory and Beck depression inventory. Cognitive functions were evaluated using Wechsler's Intelligence Scale for Children-Revised (WISC-R) or the Wechsler's Adult Intelligence Scale-Revised (WAIS-R) tests, which were adapted to Turkish children. Performance and total IQ scores (94.0 +/- 16.8 and 92.2 +/- 16.5) were significantly low as compared to the control group (112.1 +/- 18.9 and 105.4 +/- 14.2) (p = .007 and p = .02). Abnormal MRI findings were found in 33.3 % (6/18). Three out of 18 patients (16.6%) had abnormal auditory while 5 out of 17 Patients (29.5%) displayed abnormal visual EPs. Abnormal findings in MRI, cognitive examination, and electrophysiologic testing were not associated with age at diagnosis, radiotherapy doses, intermediate/high-dose systemic methotrexate administration or central nervous system involvement. But more patients must be studied to demonstrate discrete outcomes of neurotoxicity In long-term survivors of childhood le leukemia.
- «
- 1 (current)
- 2
- 3
- »
